NEW YORK – The National Institutes of Health has launched a clinical trial in which it aims to generate immune profiles of up to 2,000 adults hospitalized with confirmed or presumptive cases of COVID-19.
Fluidigm's mass cytometry platform and its Maxpar Direct Immune Profiling Assay will be one of the primary technologies used in the study, allowing researchers to measure multiplexed panels of immune proteins at the single-cell level.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.